Plain-English translation of NCT06417008 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a combination of two medications— and —to treat advanced lung cancer that has an EGFR genetic mutation. The study will first test different doses to find the safest and most effective combination, then compare this combination to alone in a larger group of patients. Researchers want to know if using both medications together helps people with this type of lung cancer live longer and feel better.
Some patients with advanced lung cancer have tumors with an EGFR mutation, which means their cancer cells have a specific genetic change. This medication combination is designed to target that change more effectively than current treatments alone, potentially offering patients a better chance of controlling their cancer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive one medication as an intravenous infusion (through an IV) during your first treatment cycle, then every two weeks after that. You will also take a daily pill at home. Each treatment cycle lasts 28 days. The study has two parts: first, researchers will test different doses to find the best combination, then a larger group will compare the two-medication combination to the pill alone to see which works better.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China